The fact
This revision follows an analysis of the biotech lab's outlook.
The stock could benefit from promising clinical results expected by late 2026.
Click the link to read an article on the topic:
This revision follows an analysis of the biotech lab's outlook.
The stock could benefit from promising clinical results expected by late 2026.